Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumours

Official Title

Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumours

Summary:

First, the investigators plan to use a retrospective analysis to determine the clinical landscape of neurofibromatosis (NF)1-associated malignant peripheral nerve sheath tumour (MPNST) and precursor lesions (e.g., atypical or nodular plexiform neurofibromas). A worldwide database will be established, collecting, in a standardized manner, histologic, immunohistochemical, molecular, radiographic, treatment, and related clinical data from centres worldwide with expertise in these NF1-related cancers. Although retrospective in nature, the resulting data from this registry may reveal previously unanticipated patterns, similar to the INFACT effort outcome. This registry would then allow the acquisition of data associated with MPNST biospecimens collected under associated banks (frozen or paraffin-embedded, germline (or normal tissue DNA) samples, and any previously somatic whole-exome or whole-genome sequencing data for aggregate analyses). Second, the investigators plan to co-register patients to institutional banks in order to prospectively collect MPNST samples for analysis. These patients will be consented in order to collect the above information and for banking of tumour tissue and future studies that include genomic characterization of the tumours.

Trial Description

Primary Outcome:

  • Histologic characteristics of malignant peripheral nerve sheath tumour (MPNST)
  • Immunohistochemical characteristics of malignant peripheral nerve sheath tumour (MPNST)
  • Molecular characteristics of malignant peripheral nerve sheath tumour (MPNST)
  • Radiographic characteristics of malignant peripheral nerve sheath tumour (MPNST)
  • Treatment given to patients with malignant peripheral nerve sheath tumour (MPNST)
  • Future genomic characterization of malignant peripheral nerve sheath tumour (MPNST)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society